SAN DIEGO, June 09, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NYSE MKT:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today reported financial results for the fiscal fourth quarter of 2016, issued its full-year fiscal 2017 outlook and affirmed its long-range guidance. Net loss was $8.4 million, or $0.09 per share, for the fiscal fourth quarter of 2016, as compared to $7.8 million, or $0.10 per share, for the fiscal fourth quarter of 2015.
Organovo reported fiscal fourth-quarter total revenue of $0.5 million, which consisted primarily of collaborations and product and service revenue. Total revenue increased 105 percent versus the comparable period of fiscal 2015 and 67 percent versus the fiscal third quarter of 2016. Collaborations revenue, which primarily represents revenue from the Company’s research agreements with L’Oreal USA and Merck & Co., increased by $0.4 million from the year-ago period.
